de JP Morgan Chase Acadia Pharmaceuticals ACAD Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 6.06 M | Vender |
234,706
-28,385
| -11% | -USD 625 k | ﹤0.01% | 3281 |
|
|
2026
Q1 | USD 5.54 M | Vender |
263,091
-7,735
| -3% | -USD 185 k | ﹤0.01% | 3233 |
|
|
2025
Q4 | USD 7.23 M | Vender |
270,826
-55,095
| -17% | -USD 1.32 M | ﹤0.01% | 2988 |
|
|
2025
Q3 | USD 6.96 M | Comprar |
325,921
+13,984
| +4% | +USD 331 k | ﹤0.01% | 3067 |
|
|
2025
Q2 | USD 6.73 M | Vender |
311,937
-12,788
| -4% | -USD 238 k | ﹤0.01% | 2886 |
|
|
2025
Q1 | USD 5.39 M | Vender |
324,725
-388,635
| -54% | -USD 7.06 M | ﹤0.01% | 3100 |
|
|
2024
Q4 | USD 13.1 M | Comprar |
713,360
+272,236
| +62% | +USD 4.39 M | ﹤0.01% | 2446 |
|
|
2024
Q3 | USD 6.78 M | Vender |
441,124
-187,125
| -30% | -USD 3.12 M | ﹤0.01% | 2966 |
|
|
2024
Q2 | USD 10.2 M | Comprar |
628,249
+153,245
| +32% | +USD 2.47 M | ﹤0.01% | 2455 |
|
|
2024
Q1 | USD 8.78 M | Vender |
475,004
-185,896
| -28% | -USD 4.61 M | ﹤0.01% | 2601 |
|
|
2023
Q4 | USD 20.7 M | Comprar |
660,900
+202,985
| +44% | +USD 4.85 M | ﹤0.01% | 1826 |
|
|
2023
Q3 | USD 9.5 M | Comprar |
457,915
+176,923
| +63% | +USD 4.81 M | ﹤0.01% | 2286 |
|
|
2023
Q2 | USD 6.73 M | Vender |
280,992
-1,303,792
| -82% | -USD 29 M | ﹤0.01% | 2636 |
|
|
2023
Q1 | USD 29.8 M | Vender |
1,584,784
-510,707
| -24% | -USD 9.7 M | ﹤0.01% | 1369 |
|
|
2022
Q4 | USD 33.4 M | Comprar |
2,095,491
+236,530
| +13% | +USD 3.7 M | ﹤0.01% | 1327 |
|
|
2022
Q3 | USD 30.4 M | Vender |
1,858,961
-47,759
| -3% | -USD 773 k | ﹤0.01% | 1307 |
|
|
2022
Q2 | USD 26.9 M | Vender |
1,906,720
-403,635
| -17% | -USD 7.53 M | ﹤0.01% | 1398 |
|
|
2022
Q1 | USD 56 M | Comprar |
2,310,355
+108,179
| +5% | +USD 2.62 M | 0.01% | 1105 |
|
|
2021
Q4 | USD 51.4 M | Vender |
2,202,176
-113,440
| -5% | -USD 2.28 M | 0.01% | 1200 |
|
|
2021
Q3 | USD 38.5 M | Vender |
2,315,616
-65,952
| -3% | -USD 1.27 M | ﹤0.01% | 1319 |
|
|
2021
Q2 | USD 58.1 M | Comprar |
2,381,568
+979,855
| +70% | +USD 22.1 M | 0.01% | 1146 |
|
|
2021
Q1 | USD 36.2 M | Comprar |
1,401,713
+459,903
| +49% | +USD 20.2 M | ﹤0.01% | 1319 |
|
|
2020
Q4 | USD 50.3 M | Comprar |
941,810
+71,968
| +8% | +USD 3.57 M | 0.01% | 1066 |
|
|
2020
Q3 | USD 35.1 M | Vender |
869,842
-206,713
| -19% | -USD 8.93 M | 0.01% | 1159 |
|
|
2020
Q2 | USD 52.2 M | Vender |
1,076,555
-20,751
| -2% | -USD 996 k | 0.01% | 869 |
|
|
2020
Q1 | USD 46.4 M | Vender |
1,097,306
-24,910
| -2% | -USD 1.03 M | 0.01% | 836 |
|
|
2019
Q4 | USD 48 M | Comprar |
1,122,216
+25,090
| +2% | +USD 1.09 M | 0.01% | 986 |
|
|
2019
Q3 | USD 39.5 M | Vender |
1,097,126
-77,637
| -7% | -USD 2.35 M | 0.01% | 1072 |
|
|
2019
Q2 | USD 31 M | Comprar |
1,174,763
+367,547
| +46% | +USD 9.39 M | 0.01% | 1257 |
|
|
2019
Q1 | USD 21.7 M | Vender |
807,216
-13,955
| -2% | -USD 326 k | ﹤0.01% | 1489 |
|
|
2018
Q4 | USD 13.3 M | Comprar |
821,171
+10,184
| +1% | +USD 198 k | ﹤0.01% | 1787 |
|
|
2018
Q3 | USD 16.8 M | Comprar |
810,987
+312,648
| +63% | +USD 4.92 M | ﹤0.01% | 1801 |
|
|
2018
Q2 | USD 7.61 M | Vender |
498,339
-1,429,257
| -74% | -USD 25.5 M | ﹤0.01% | 2360 |
|
|
2018
Q1 | USD 43.3 M | Vender |
1,927,596
-11,784
| -0.6% | -USD 326 k | 0.01% | 1018 |
|
|
2017
Q4 | USD 58.4 M | Comprar |
1,939,380
+59,556
| +3% | +USD 1.9 M | 0.01% | 905 |
|
|
2017
Q3 | USD 72.1 M | Vender |
1,879,824
-3,342
| -0.2% | -USD 109 k | 0.02% | 755 |
|
|
2017
Q2 | USD 52.5 M | Comprar |
1,883,166
+96,742
| +5% | +USD 2.88 M | 0.01% | 884 |
|
|
2017
Q1 | USD 61.4 M | Vender |
1,786,424
-273,408
| -13% | -USD 9.7 M | 0.01% | 840 |
|
|
2016
Q4 | USD 59.4 M | Comprar |
2,059,832
+505,213
| +32% | +USD 13.4 M | 0.01% | 801 |
|
|
2016
Q3 | USD 49.5 M | Comprar |
1,554,619
+657,771
| +73% | +USD 22.3 M | 0.01% | 843 |
|
|
2016
Q2 | USD 29.1 M | Vender |
896,848
-137,474
| -13% | -USD 4.6 M | 0.01% | 1145 |
|
|
2016
Q1 | USD 28.9 M | Comprar |
1,034,322
+24,986
| +2% | +USD 545 k | 0.01% | 1098 |
|
|
2015
Q4 | USD 36 M | Vender |
1,009,336
-6,813
| -0.7% | -USD 240 k | 0.01% | 972 |
|
|
2015
Q3 | USD 33.6 M | Vender |
1,016,149
-139,095
| -12% | -USD 5.79 M | 0.01% | 972 |
|
|
2015
Q2 | USD 48.4 M | Vender |
1,155,244
-204,444
| -15% | -USD 7.91 M | 0.01% | 889 |
|
|
2015
Q1 | USD 44.3 M | Vender |
1,359,688
-135,209
| -9% | -USD 4.65 M | 0.01% | 954 |
|
|
2014
Q4 | USD 47.5 M | Comprar |
1,494,897
+537,419
| +56% | +USD 15.2 M | 0.01% | 954 |
|
|
2014
Q3 | USD 23.7 M | Comprar |
957,478
+7,669
| +0.8% | +USD 179 k | 0.01% | 1328 |
|
|
2014
Q2 | USD 21.5 M | Comprar |
949,809
+107,952
| +13% | +USD 2.25 M | 0.01% | 1302 |
|
|
2014
Q1 | USD 20.5 M | Comprar |
841,857
+21,658
| +3% | +USD 548 k | 0.01% | 1298 |
|
|
2013
Q4 | USD 20.5 M | Vender |
820,199
-71,998
| -8% | -USD 1.7 M | 0.01% | 1316 |
|
|
2013
Q3 | USD 24.5 M | Comprar |
892,197
+4,665
| +0.5% | +USD 97.5 k | 0.01% | 1195 |
|
|
2013
Q2 | USD 16.1 M | Comprar |
+887,532
| Nuevas | +USD 12.2 M | 0.01% | 1382 |
|
Otros fondos que tienen ACAD en su cartera
BBA
Posición de JP Morgan Chase en ACAD: resumen de T2 2026
JP Morgan Chase redujo su participación en Acadia Pharmaceuticals (ACAD) en 11% durante T2 2026, al vender acciones por un valor estimado de USD 625 k, y conservó 234,706 acciones valuadas en USD 6.06 M. La posición representa ﹤0.01% de la cartera y ocupa el puesto #3281.
JP Morgan Chase reportó por primera vez una posición en ACAD en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. La posición alcanzó su máximo de USD 72.1 M en T3 2017. Al cierre de T2 2026, 354 fondos que sigue Wall St. Rank mantienen una posición en ACAD.
- Al cierre de T2 2026, JP Morgan Chase tenía 234,706 acciones de Acadia Pharmaceuticals con un valor de USD 6.06 M.
- JP Morgan Chase vendió 28,385 acciones de Acadia Pharmaceuticals en T2 2026, por un valor estimado de USD 625 k.
- Acadia Pharmaceuticals representó ﹤0.01% de la cartera de JP Morgan Chase en T2 2026 y fue su posición número 3281.
- JP Morgan Chase reportó por primera vez una posición en Acadia Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- La posición de JP Morgan Chase en Acadia Pharmaceuticals alcanzó su máximo de USD 72.1 M en T3 2017.
- Al cierre de T2 2026, 354 fondos que sigue Wall St. Rank tenían Acadia Pharmaceuticals en cartera.
Según el Informe 13F de JP Morgan Chase correspondiente a T2 2026, presentado el 12 ago 2026.